{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T21:51:05Z","timestamp":1697406665222},"reference-count":9,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.patbio.2008.07.028","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T11:49:34Z","timestamp":1227527374000},"page":"435-438","source":"Crossref","is-referenced-by-count":3,"title":["Pseudomonas aeruginosa et b\u00eata-lactamines \u00e0 l\u2019heure de l\u2019Europe"],"prefix":"10.1016","volume":"56","author":[{"given":"J.-D.","family":"Cavallo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"M\u00e9rens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2008.07.028_bib1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1046\/j.1469-0691.2000.00086.x","article-title":"Apparent differences in antimicrobial susceptibility as a consequence of national guidelines","volume":"6","author":"Leegard","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.patbio.2008.07.028_bib2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Khalmeter","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.patbio.2008.07.028_bib3","doi-asserted-by":"crossref","unstructured":"European Committee for Antimicrobial Susceptibility Testing. Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 2000; 6:570\u20132.","DOI":"10.1046\/j.1469-0691.2000.00178.x"},{"key":"10.1016\/j.patbio.2008.07.028_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.diagmicrobio.2007.01.004","article-title":"Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamics assessment","volume":"58","author":"DeRyke","year":"2007","journal-title":"Diag Microbiol Infect Dis"},{"key":"10.1016\/j.patbio.2008.07.028_bib5","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1128\/AAC.01586-06","article-title":"Concentration-effet relationship of cefatzidime explains why the time above MIC is 40\u00a0% for a static effect in vivo","volume":"51","author":"Mouton","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.patbio.2008.07.028_bib6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/jac\/dkm536","article-title":"Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation","volume":"61","author":"Frei","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.patbio.2008.07.028_bib7","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1086\/528712","article-title":"Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam\u00a0: implications on the appropriateness of the resistance breakpoint","volume":"46","author":"Tam","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.patbio.2008.07.028_bib8","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1086\/344186","article-title":"Use of appropriate breakpoints in antimicrobial surveillance studies","volume":"35","author":"Jacobs","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.patbio.2008.07.028_bib9","unstructured":"Joly-Guillou M-L, Cavallo J-D, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, et al. Comparative activity of Meropenem, Imipenem and Piperacillin\/tazobactam against 1118 bacteria involved in hospital infections: a French multicenter study. European Congress and Clinical Microbiology and Infectious Diseases, 2008 April 19-22; Barcelona. Poster P612."}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811408002095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811408002095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T17:56:58Z","timestamp":1557943018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811408002095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":9,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0369811408002095"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2008.07.028","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}